Compare SITM & ARWR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SITM | ARWR |
|---|---|---|
| Founded | 2003 | 2003 |
| Country | United States | United States |
| Employees | 395 | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.7B | 9.6B |
| IPO Year | 2019 | 1993 |
| Metric | SITM | ARWR |
|---|---|---|
| Price | $330.20 | $63.61 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 10 |
| Target Price | ★ $325.63 | $63.70 |
| AVG Volume (30 Days) | 330.0K | ★ 2.2M |
| Earning Date | 02-04-2026 | 02-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $281,486,000.00 | ★ $829,448,000.00 |
| Revenue This Year | $58.61 | N/A |
| Revenue Next Year | $39.94 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 59.04 | ★ 23258.15 |
| 52 Week Low | $105.40 | $9.57 |
| 52 Week High | $387.52 | $72.36 |
| Indicator | SITM | ARWR |
|---|---|---|
| Relative Strength Index (RSI) | 44.12 | 50.93 |
| Support Level | $352.42 | $65.94 |
| Resistance Level | $382.72 | $69.71 |
| Average True Range (ATR) | 18.04 | 3.43 |
| MACD | -5.55 | -1.40 |
| Stochastic Oscillator | 3.43 | 32.66 |
SiTime Corp is a provider of silicon timing systems solutions. The company designs develops and sell silicon timing systems solutions for different industries including automotive, infrastructure, aerospace-defense, consumer, internet of things, consumer and industrials. Its product offerings include Stratum 3E DCOCXOs, Programmable OCXOs, MHz Oscillators, 32.768 kHz Oscillators, Embedded Resonators, Precision MHz Super-TCXOs, and Ruggedized Oscillators. It sells its products around Taiwan, Hong Kong, the United States, and other regions and generates the majority of its revenue from Taiwan.
Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting cardiovascular, Cardiometabolic, Central Nervous System, Pulmonary, Liver, Muscular, and Complement Mediated Disease. It majority products are liver disease curable.